Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$70.30

1.73 (2.52%)

, NBIX

Neurocrine

$51.26

0.99 (1.97%)

05:38
10/06/16
10/06
05:38
10/06/16
05:38

Alnylam downgraded to Equal Weight from Overweight at Barclays

Barclays analyst Geoff Meacham downgraded Alnylam Pharmaceuticals (ALNY) to Equal Weight saying he views other SMid cap biotech names as more attractive following the company's recent pipeline setbacks. The analyst removed Revusiran sales from his Alnylam model after the program was discontinued yesterday and he cut his price target for the shares to $50 from $85. Meacham lists Neurocrine (NBIX), Prothena (PTRA) and Incyte (INCY) as names he finds more attractive over the next 12 months. Alnylam is trading down 44% in pre-market trading to $39.25.

ALNY

Alnylam

$70.30

1.73 (2.52%)

NBIX

Neurocrine

$51.26

0.99 (1.97%)

PRTA

Prothena

$62.92

1.11 (1.80%)

INCY

Incyte

$95.69

1.52 (1.61%)

  • 07

    Oct

  • 07

    Oct

  • 14

    Oct

  • 06

    Nov

ALNY Alnylam
$70.30

1.73 (2.52%)

08/22/16
WEDB
08/22/16
NO CHANGE
WEDB
Intellia Therapeutics data positive, says Wedbush
Wedbush analyst David Nierengarten says that additional data on Intella's (NTLA) TTR program in mice was "meaningful" and indicates that the program compares favorably with competing products. The analyst says that competing programs, including those of Alnylam (ALNY) and Ionis (IONS) have shown "only a transient benefit." He reiterates a $38 price target and Outperform rating on Intella.
09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).
09/15/16
FBRC
09/15/16
INITIATION
Target $82
FBRC
Underperform
FBR calls Alexion overvalued, starts shares at Underperform
FBR Capital analyst Christopher James initiated coverage of Alexion Pharmaceuticals (ALXN) with an Underperform rating and $82 price target. The biotech focused on patients with ultra-rare disorders closed yesterday up $2.63 to $129.42. Alexion shares are overpriced as the company is facing a competitive near-term landscape, particularly from Alnylam's (ALNY) ALN-CC5, James tells investors in a research note. Further, near-term expansion into additional indications will be challenging given the recent failed study with eculizumab in refractory generalized myasthenia gravis, the analyst contends. He also sees possible pricing pressures from biosimilars, including an Amgen (AMGN) biosimilar product in development. James this morning also initiated Achillion Pharmaceuticals (ACHN) and Arena Pharmaceuticals (ARNA) with Outperform ratings.
09/28/16
JANY
09/28/16
INITIATION
Target $74
JANY
Neutral
Alnylam initiated with a Neutral at Janney Capital
Janney Capital analyst Roy Buchanan initiated Alnylam with a Neutral and a $74 fair value estimate. The analyst is not confident about the outcome for the pivotal study for patisiran in transthyretin familial amyloid neuropathy, expected in about 12 months, and give patisiran a 50% chance of success.
NBIX Neurocrine
$51.26

0.99 (1.97%)

10/04/16
LEER
10/04/16
INITIATION
Target $70
LEER
Outperform
Neurocrine reinstated with an Outperform at Leerink
Leerink analyst Paul Matteis resumed coverage of Neurocrine with an Outperform rating and $70 price target.
06/29/16
HCWC
06/29/16
INITIATION
Target $80
HCWC
Buy
Neurocrine initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein started Neurocrine Biosciences with a Buy rating and $80 price target.
06/06/16
BMOC
06/06/16
NO CHANGE
BMOC
Neurocrine price target raised to $66 from $57 at BMO Capital
BMO Capital raised its price target on Neutrocirne (NBIX) as it believes that the company's elagolix drug has a positive read through from data recently presented by AbbVie (ABBV). .
09/23/16
LEER
09/23/16
NO CHANGE
LEER
Outperform
Positive data paves way for Teva SD-809 indication, says Leerink
Leerink analyst Jason Gerberry says the AIM-TD study readout clinically de-risks Teva's (TEVA) SD-809 opportunity for tardive dyskinesia, with the investor focus shifting to market size and competitive differentiation versus Neurocrine's (NBIX) valbenazine. The analyst believes Teva's SD-809 is well positioned to compete against valbenazine with an equally efficacious and well tolerated drug. Further, he expects Teva to exit 2017 with a broader label. Gerberry reiterates an Outperform rating on Teva's shares.
PRTA Prothena
$62.92

1.11 (1.80%)

09/27/16
RBCM
09/27/16
NO CHANGE
RBCM
Prothena CEO change 'neutral, natural, and positive' says RBC Capital
Afte Prothena announced its CEO was taking a medical leave and that it was elevating its COO, Gene Kinney, to interim CEO, RBC Capital analyst Michael Yee says "this a a neutral and natural positive development." Yee reports that Kinney " has been generally in charge of and overseen the R&D and clinical development of their 3 lead programs and involved in leading discussions with the FDA." The analyst believes that the company had previously been planning for succession and that investors should not be surprised by this development, as they knew that the CEO had health problems. Yee keeps an Outperform rating on the shares.
09/27/16
UBSW
09/27/16
NO CHANGE
Target $73
UBSW
Buy
Prothena management has continuity during CEO leave of absence, says UBS
UBS analyst Jeffrey Hung noted that Prothena's COO Gene Kinney will lead the company while its CEO, Dale Schenk, is on a medical leave of absence. Hung notes that the NEOD001 strategy is already largely in place and he believes the Board's confidence in Kinney, combined with his recent promotion, points to the potential for a natural succession. The analyst keeps a Buy rating and $73 price target on Prothena shares.
06/10/16
RBCM
06/10/16
NO CHANGE
RBCM
Prothena data positive, says RBC Capital
RBc Capital believes that the Phase I data for Prothena's antibody program, '003, was positive. The firm thinks the treatment "could be a new psoriasis drug or go after other big inflammatory markets." The firm expects '003 to begin to get attention from investors, and it views the product as "somewhat de-risked." RBC keeps an Outperform rating on the shares.
08/03/16
LTCO
08/03/16
NO CHANGE
Target $80
LTCO
Buy
Prothena price target raised to $80 from $77 at Ladenburg
Ladenburg Thalmann analyst Robert Hazlett said the recently released clinical data from the Phase 1/2 study of NEOD001 continue to point to promising organ responses that do not appear to be related to prior plasma cell directed therapy. Noting there are catalysts upcoming for NEOD001, PRX002 and PRX003, the analyst raised his price target on the stock to $80, adding that he assigns a 70% probability of Prothena operating independently and a 30% probability to a takeover.
INCY Incyte
$95.69

1.52 (1.61%)

09/29/16
09/29/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. eBay (EBAY) upgraded to Buy from Hold at Deutsche Bank with analyst Ross Sandler saying eBay is likely to outperform Internet peers over the next two years now that its re-platforming is in the latter stages. 2. BlackBerry (BBRY) upgraded to Neutral from Underperform at Macquarie with analyst Gus Papageorgiou saying he expects operations to stabilize and profitability to return next year. 3. Endo (ENDP) upgraded to Outperform from Market Perform at Northland. 4. Rex Energy (REXX) upgraded to Hold from Sell at Stifel with analyst Michael Scialla saying the production cut may not actually occur, but he believes that other factors, along with positive commentary from OPEC, "appears to be building an oil price floor of $40." 5. Incyte (INCY) upgraded to Outperform from Market Perform at Raymond James with analyst Reni Benjamin saying Epacadostat plus pembrolizumab, should ;the results be confirmed in the ongoing Phase III study, could effectively compete with ipilimumab and nivolumab. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/29/16
RAJA
09/29/16
UPGRADE
Target $115
RAJA
Outperform
Incyte upgraded to Outperform from Market Perform at Raymond James
Raymond James analyst Reni Benjamin upgraded Incyte to Outperform with a $115 price target following the release of an abstract showcasing "positive" long-term follow-up results for epacadostat in melanoma. Epacadostat plus pembrolizumab, should ;the results be confirmed in the ongoing Phase III study, could effectively compete with ipilimumab and nivolumab, Benjamin tells investors in a research note.
09/21/16
09/21/16
NO CHANGE

RBC identifies top biotech takeover candidates
RBC Capital identified the following names as its top potential takeover candidates in the biotech space: ARIAD (ARIA), Spark Therapeutics (ONCE), BioMarin (BMRN), Aerie Pharmaceuticals (AERI), Intra-Cellular (ITCI), TESARO (TSRO), Incyte (INCY), Sarepta (SRPT), and Puma Biotechnology (PBYI). The firm thinks that investors are underestimating the positive impact that M&A will have on biotech stock prices.
08/22/16
GSCO
08/22/16
NO CHANGE
GSCO
Goldman lists companies to be in focus after Medivation deal
After Pfizer (PFE) announced it has agreed to acquire Medivation (MDVN) for $81.50 per share in cash, Goldman Sachs analyst Salveen Richter said he expects a focus on other commercial small-to-mid-cap cancer companies, including Incyte (INCY), Seattle Genetics (SGEN), ARIAD (ARIA) and Exelixis (EXEL). Also noting that Sanofi (SNY), which was pursuing Medivation, has recently suggested an interest in a rare disease transaction up to potentially as large as $20B, he would expect rare disease companies of that size - such as BioMarin (BMRN), Amicus (FOLD) and Ultragenyx (RARE) - to be in focus as well.

TODAY'S FREE FLY STORIES

LNKD

LinkedIn

, MSFT

Microsoft

$61.37

1.42 (2.37%)

14:58
12/08/16
12/08
14:58
12/08/16
14:58
Hot Stocks
NYSE informs SEC of plans to delist LinkedIn stock after Microsoft deal closing »

In a regulatory filing,…

LNKD

LinkedIn

MSFT

Microsoft

$61.37

1.42 (2.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PVTB

PrivateBancorp

$52.39

0.25 (0.48%)

, CM

CIBC

$84.66

0.96 (1.15%)

14:55
12/08/16
12/08
14:55
12/08/16
14:55
Hot Stocks
PrivateBancorp at highs as report claims third party approach »

PrivateBancorp (PVTB),…

PVTB

PrivateBancorp

$52.39

0.25 (0.48%)

CM

CIBC

$84.66

0.96 (1.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

AVGO

Broadcom

$168.55

3.79 (2.30%)

14:49
12/08/16
12/08
14:49
12/08/16
14:49
Options
Broadcom options imply 6.8% move in share price post-earnings, below median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

SPWR

SunPower

$7.95

0.99 (14.22%)

14:45
12/08/16
12/08
14:45
12/08/16
14:45
Options
SunPower call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNSR

Finisar

$32.24

0.51 (1.61%)

14:43
12/08/16
12/08
14:43
12/08/16
14:43
Technical Analysis
Finisar technical comments ahead of earnings news, potential bearish pattern »

The key technical feature…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

MBLY

Mobileye

$35.64

-1.735 (-4.64%)

14:40
12/08/16
12/08
14:40
12/08/16
14:40
Recommendations
Mobileye analyst commentary  »

Mobileye comments…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 10

    Jan

MGNX

MacroGenics

$26.47

-1.77 (-6.27%)

14:40
12/08/16
12/08
14:40
12/08/16
14:40
Conference/Events
MacroGenics to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

14:40
12/08/16
12/08
14:40
12/08/16
14:40
General news
FOMC Forecast revisions »

FOMC Forecast revisions…

AZO

AutoZone

$811.19

1.315 (0.16%)

, ORLY

O'Reilly Automotive

$285.20

7.52 (2.71%)

14:39
12/08/16
12/08
14:39
12/08/16
14:39
Hot Stocks
Icahn negative on automotive replacement retailers »

Carl Icahn, while…

AZO

AutoZone

$811.19

1.315 (0.16%)

ORLY

O'Reilly Automotive

$285.20

7.52 (2.71%)

AMZN

Amazon.com

$770.42

5.7 (0.75%)

AAP

Advance Auto Parts

$177.03

0.25 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

ESRX

Express Scripts

$75.85

-0.88 (-1.15%)

, VRX

Valeant

$15.54

0.455 (3.02%)

14:38
12/08/16
12/08
14:38
12/08/16
14:38
Hot Stocks
Express Scripts denies being anything 'like Philidor' »

Contacted by The Fly to…

ESRX

Express Scripts

$75.85

-0.88 (-1.15%)

VRX

Valeant

$15.54

0.455 (3.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

  • 16

    Feb

DAL

Delta Air Lines

$51.69

0.59 (1.15%)

14:36
12/08/16
12/08
14:36
12/08/16
14:36
Conference/Events
Delta Air Lines to host investor meeting »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

MTN

Vail Resorts

$161.72

-1.01 (-0.62%)

14:36
12/08/16
12/08
14:36
12/08/16
14:36
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

AVGO

Broadcom

$168.55

3.79 (2.30%)

, COO

Cooper Companies

$168.47

0.08 (0.05%)

14:36
12/08/16
12/08
14:36
12/08/16
14:36
Earnings
Notable companies reporting after market close »

Notable companies…

AVGO

Broadcom

$168.55

3.79 (2.30%)

COO

Cooper Companies

$168.47

0.08 (0.05%)

FNSR

Finisar

$32.24

0.51 (1.61%)

RH

Restoration Hardware

$38.65

0.7137 (1.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

  • 08

    Dec

  • 08

    Dec

  • 13

    Dec

IWM

iShares Trust Russell 2000 Index Fund

$137.92

2.015 (1.48%)

14:30
12/08/16
12/08
14:30
12/08/16
14:30
Options
Big option play opened in the Small Cap Fund as shares reach new highs »

Big option play opened in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHK

Chesapeake

$7.52

-0.065 (-0.86%)

14:30
12/08/16
12/08
14:30
12/08/16
14:30
Hot Stocks
Icahn says does not own shares of Chesapeake »

Carl Icahn is speaking on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLO

Valero

$68.72

1.18 (1.75%)

, WNR

Western Refining

$39.18

-0.32 (-0.81%)

14:29
12/08/16
12/08
14:29
12/08/16
14:29
Hot Stocks
Icahn says refining stocks sold off because of EPA »

Carl Icahn is speaking on…

VLO

Valero

$68.72

1.18 (1.75%)

WNR

Western Refining

$39.18

-0.32 (-0.81%)

TSO

Tesoro

$90.89

-1.11 (-1.21%)

MPC

Marathon Petroleum

$50.14

0.485 (0.98%)

PSX

Phillips 66

$87.91

0.9 (1.03%)

DK

Delek US

$24.13

0.75 (3.21%)

HFC

HollyFrontier

$33.95

0.93 (2.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:27
12/08/16
12/08
14:27
12/08/16
14:27
Hot Stocks
Icahn says involved with board, news will be out in next week »

Carl Icahn, while…

FB

Facebook

$117.95

0.64 (0.55%)

, TWTR

Twitter

$19.39

-0.0942 (-0.48%)

14:27
12/08/16
12/08
14:27
12/08/16
14:27
Periodicals
Snapchat hits $300M in 2016 sales, sets $1B goal for 2017, The Information says »

Snapchat parent Snap set…

FB

Facebook

$117.95

0.64 (0.55%)

TWTR

Twitter

$19.39

-0.0942 (-0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LVS

Las Vegas Sands

$62.49

-0.19 (-0.30%)

, MGM

MGM Resorts

$30.52

0.57 (1.90%)

14:26
12/08/16
12/08
14:26
12/08/16
14:26
Periodicals
Macau government to slash ATM withdrawl limit, SCMP reports »

China's government…

LVS

Las Vegas Sands

$62.49

-0.19 (-0.30%)

MGM

MGM Resorts

$30.52

0.57 (1.90%)

WYNN

Wynn Resorts

$101.99

-0.19 (-0.19%)

MPEL

Melco Crown

$19.55

0.13 (0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KBH

KB Home

$17.32

0.77 (4.65%)

14:25
12/08/16
12/08
14:25
12/08/16
14:25
Options
KB Home call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jan

LVS

Las Vegas Sands

$62.50

-0.18 (-0.29%)

, MGM

MGM Resorts

$30.55

0.595 (1.99%)

14:21
12/08/16
12/08
14:21
12/08/16
14:21
Periodicals
Breaking Periodicals news story on Las Vegas Sands, MGM Resorts, Wynn Resorts, Melco Crown »

Chinese government to…

LVS

Las Vegas Sands

$62.50

-0.18 (-0.29%)

MGM

MGM Resorts

$30.55

0.595 (1.99%)

WYNN

Wynn Resorts

$101.99

-0.19 (-0.19%)

MPEL

Melco Crown

$19.55

0.13 (0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$125.39

0.82 (0.66%)

14:19
12/08/16
12/08
14:19
12/08/16
14:19
Periodicals
California weighing tax for online video streaming, Armstrong Economics says »

Officials from Pasadena…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WYNN

Wynn Resorts

$101.99

-0.19 (-0.19%)

, LVS

Las Vegas Sands

$62.59

-0.09 (-0.14%)

14:19
12/08/16
12/08
14:19
12/08/16
14:19
Hot Stocks
Wynn Resorts, Las Vegas Sands fall sharply »

Several casino stocks,…

WYNN

Wynn Resorts

$101.99

-0.19 (-0.19%)

LVS

Las Vegas Sands

$62.59

-0.09 (-0.14%)

MGM

MGM Resorts

$30.55

0.595 (1.99%)

MPEL

Melco Crown

$19.55

0.13 (0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RAI

Reynolds American

$54.90

-0.04 (-0.07%)

, PM

Philip Morris

$89.72

-0.155 (-0.17%)

14:18
12/08/16
12/08
14:18
12/08/16
14:18
Hot Stocks
U.S. Surgeon General: E-cigarettes pose 'significant' risk to young people »

U.S. Surgeon General…

RAI

Reynolds American

$54.90

-0.04 (-0.07%)

PM

Philip Morris

$89.72

-0.155 (-0.17%)

MO

Altria Group

$65.42

0.01 (0.02%)

VGR

Vector Group

$21.96

0.28 (1.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDX

FedEx

$196.90

0.78 (0.40%)

14:18
12/08/16
12/08
14:18
12/08/16
14:18
Technical Analysis
FedEx extends recent rally, bullish pattern has more room to run »

The shares were last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.